David Rickman, Ph.D., is a molecular biologist and an Assistant Professor of Pathology and Laboratory Medicine. Dr. Rickman’s interest in cancer biology began during his post-doctoral fellowship at the University of Michigan Medical School where he used genome-wide approaches to characterize malignant gliomas. He then joined France’s Ligue Nationale Contre le Cancer based in Paris as a project leader for a national cancer biomarker program that aimed to identify clinically relevant biomarkers for multiple cancer types. Dr. Rickman’s research lab is focused on elucidating the role of ETS family members and N-Myc in coordinating gene regulation, chromatin 3D architecture and response to chemotherapy in the context of prostate adenocarcinoma and neuroendocrine prostate cancer. To this end, Dr. Rickman’s lab has been developing in vitro and in vivo model systems that better mimic the context of the expression of these factors in vivo.